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Key messages
What is already known about this subject?
 ► The introduction of ACR/EULAR rheumatoid 
arthritis (RA) classification criteria has impacted 
positively on early diagnosis and treatment of 
RA leading to better outcomes. By the same 
token, broader criteria have led to the inclusion 
of patients with milder and more heterogenous 
disease. This, together with the inability 
to precisely predict disease prognosis and 
treatment response at the individual patient 
levels, emphasise the need to identify patients 
at risk of accelerated structural damage 
progression and fast- track aggressive/biological 
therapies to patients with poor prognosis.
AbsTrACT
Objective To establish whether synovial pathobiology 
improves current clinical classification and prognostic 
algorithms in early inflammatory arthritis and identify 
predictors of subsequent biological therapy requirement.
Methods 200 treatment- naïve patients with early 
arthritis were classified as fulfilling ra1987 american 
college of rheumatology (acr) criteria (ra1987) or 
as undifferentiated arthritis (Ua) and patients with 
Ua further classified into those fulfilling ra2010 
acr/european league against rheumatism (eUlar) 
criteria. Treatment requirements at 12 months 
(conventional synthetic Disease Modifying antirheumatic 
Drugs (csDMarDs) vs biologics vs no- csDMarDs 
treatment) were determined. synovial tissue was 
retrieved by minimally invasive, ultrasound- guided biopsy 
and underwent processing for immunohistochemical 
(iHc) and molecular characterisation. samples were 
analysed for macrophage, plasma- cell and B- cells and 
T- cells markers, pathotype classification (lympho- myeloid, 
diffuse- myeloid or pauci- immune) by iHc and gene 
expression profiling by nanostring.
results 128/200 patients were classified as ra1987, 
25 as ra2010 and 47 as Ua. Patients classified as 
ra1987 criteria had significantly higher levels of 
disease activity, histological synovitis, degree of immune 
cell infiltration and differential upregulation of genes 
involved in B and T cell activation/function compared 
with ra2010 or Ua, which shared similar clinical and 
pathobiological features. at 12- month follow- up, a 
significantly higher proportion of patients classified as 
lympho- myeloid pathotype required biological therapy. 
Performance of a clinical prediction model for biological 
therapy requirement was improved by the integration 
of synovial pathobiological markers from 78.8% to 
89%–90%.
Conclusion The capacity to refine early clinical 
classification criteria through synovial pathobiological 
markers offers the potential to predict disease outcome 
and stratify therapeutic intervention to patients most in 
need.
InTrOduCTIOn
The introduction of new classification criteria 
for rheumatoid arthritis (RA) in 20101 has been 
demonstrated to be clinically useful with enhanced 
diagnostic sensitivity in early disease compared 
with 1987 criteria2 ; however, this is balanced by 
a lower specificity.3 4 This is of particular impor-
tance, as data suggest that approximately 40% 
of patients with early inflammatory arthritis, not 
fulfilling 1987 criteria, may spontaneously remit 
while approximately 30% will progress to RA.5 
Critically, the mechanisms underlying the tran-
sition from undifferentiated arthritis (UA) to RA 
remain unknown though it has been suggested 
that qualitative or quantitative difference within 
synovial tissue may contribute to diverse disease 
evolution and/or treatment response.6 7 Thus, 
pretreatment stratification of early inflammatory 
arthritis is important in order to target therapy 
to poor prognosis patients. Previous data suggest 
that stratifying early arthritis according to RA2010 
versus RA1987 classification criteria reveals signif-
icant clinical heterogeneity in diagnosis at 2- year 
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Key messages
What does this study add?
 ► This study analyses the largest biopsy- driven early 
inflammatory arthritis cohort to date (200 patients) 
and, through a detailed synovial cellular and molecular 
characterisation refines ACR/EULAR disease classification. 
In addition, the study identifies synovial pathobiological 
markers associated with the lympho- myeloid pathotype 
and the requirement of biological therapy at 12 months, 
reinforcing recently published data that indicate that these 
patients are affected by highly aggressive disease and 
worse radiographic outcome. Notably, these findings are 
independent from the time of diagnosis within the first 
12 months of symptoms initiation, suggesting that the so- 
called ‘window of opportunity’ is wider than 6 months and 
early stratification of biological therapies according to poor 
prognostic synovial pathobiological subtypes at disease onset 
may improve the outcome of these patients. The integration 
of synovial pathobiological markers into a logistic regression 
model improves the prediction accuracy from 78.8% 
(clinical) to 89%–90% (clinical +molecular) and enables the 
identification at disease onset of patients who subsequently 
require biological therapy. Thus, this study provides support 
to the notion that biological therapies should be started early 
in patients with poor prognosis.
How might this impact on clinical practice or future 
developments?
 ► The identification at disease onset of patients who are 
unlikely to respond to csDMARDs remains a major unmet 
need. The capacity to refine early clinical classification criteria 
through the application of synovial pathobiological markers 
and the ability to identify patients who subsequently require 
biological therapy at disease onset offer the opportunity to 
stratify therapeutic intervention to the patients most in need. 
This present study adds weight to the need to change current 
therapeutic algorithms and start biological therapies at 
disease onset in patients with poor prognosis. This is likely to 
have a major impact on disease control/remission and long- 
term disability, as notionally supported by numerous early 
intervention studies using biological therapies.
follow- up8 although subsequent analysis of synovial tissue did 
not suggest that such clinical heterogeneity translated to signif-
icant differences in synovial pathobiology.9 However, recently 
published data from a cohort of 144 patients with early RA 
have demonstrated that synovial cellular and molecular signa-
tures define prognostic and treatment response phenotypes.10 
Importantly, whether clinical heterogeneity associated with 
the introduction of the 2010 ACR/EULAR criteria can be 
explained by synovial pathobiological signatures and whether 
they associate with subsequent disease outcome, up to now, 
remain unknown.
Therefore, the aim of this study was to investigate whether in 
patients with early inflammatory arthritis synovial cellular and 
molecular signatures: (1) segregate according to clinical clas-
sification (RA1987 vs RA2010 vs UA), (2) change depending 
on symptom duration and (3) determine prognosis including 
subsequent requirement for biological therapy.
PATIEnTs And METHOds
Patients
Two hundred consecutive patients with inflammatory arthritis 
recruited at Barts Health NHS Trust as part of the multicentre 
pathobiology of early arthritis cohort (http://www. peac- mrc. 
mds. qmul. ac. uk) were included within the study. Patients were 
treatment naïve (csDMARD and steroid) and had <1 year 
symptoms.
At baseline, patients underwent collection of routine demo-
graphic data and were categorised according to the following 
criteria: (1) RA19872 or (2) UA. 2010 ACR/EULAR criteria 
for RA1 were then applied to further classify patients with UA, 
resulting in three groups: (1) RA1987 (RA1987+/RA2010+), 
(2) RA2010 (RA1987−/RA2010+) and (3) UA (RA1987−/
RA2010−). An ultrasound- guided synovial biopsy of a clinically 
active joint was performed.11 Patients were then given standard 
conventional synthetic csDMARD therapy with a treat- to- target 
approach to treatment escalation (Disease Activity Score 28 joints 
(DAS28) <3.2). Patients failing csDMARD therapy were given 
biological therapy (anti- tumour necrosis factor (TNF), tocili-
zumab or rituximab) according to the prevailing UK National 
Institute for Clinical Excellence (NICE) prescribing algorithm 
if they continued to have a DAS28 >5.1 following 6 months 
of therapy.12 At 12- month, follow- up patients were catego-
rised as follows: (1) self- limiting (SL) disease (DAS28 <3.2 and 
off csDMARD/steroid therapy) versus persistent disease (PD) 
(DAS28 >3.2 and/or csDMARD) and (2) symptomatic treatment 
(non- steroidal anti- inflammatories) versus csDMARD therapy 
versus biological ±csDMARD therapy.
synovial biopsy collection and processing
A minimum of six biopsies per patient were collected for paraffin 
embedding and if intact lining layer identified underwent histo-
pathological assessment. Synovitis score was determined using 
a previously validated scoring system.13 Following immunohis-
tochemical staining of sequentially cut slides using previously 
reported protocols for B cells (CD20), T cells (CD3), macro-
phages (CD68) and plasma cells (CD138), the degree of immune 
cell infiltration was assessed semiquantitatively (0–4).14 Biopsies 
were stratified into one of three synovial pathotypes according 
to the following criteria: (1) lympho- myeloid presence of grade 
2–3 CD20 +aggregates, (CD20 ≥2) and/or CD138 >2, (2) 
diffuse- myeloid CD68 SL ≥2, CD20 ≤1 and/or CD3 ≥1, 
CD138 ≤2 and (3) pauci- immune CD68 SL <2 and CD3, CD20, 
CD138 <1.
nanostring analysis
A minimum of six synovial samples per patient were immedi-
ately immersed in RNA- Later and RNA extraction performed 
as previously described.10 RNA samples then underwent 
profiling for the expression of 238 genes preselected based on 
previous microarray analyses of synovial tissue from patients 
with established RA15 and/or relevance to RA pathogenesis. 
Raw NanoString counts were processed using the NanoS-
tringQCPro package in R V.3.2.0. Counts were normalised 
for RNA content by global gene count normalisation and 
then log transformed (base 2). The validity of normalisation 
was then checked via box plot and scatter plot of normalised 
counts. Benjamini- Hochberg method was used to adjust for 
multiple testing, and genes were considered to be differentially 
expressed if they demonstrated an false discovery rate (FDR)- 
adjusted p<0.01.
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statistical analysis
Statistical analyses were run using R V.3.0.2. For three- way 
comparisons, the Kruskal- Wallis test was used for continuous 
and χ2 or Fisher’s exact test used for categorical variables as 
appropriate. A p<0.05 was considered statistically significant. 
Post hoc comparison tests were performed using the Dunn test 
or Bonferroni correction as appropriate.
Linear regression models
Logistic regression using forward, backward and bidirectional 
stepwise selection was employed using the glm function in R.
Gene expression predictors were selected by L1 (LASSO) 
sparse logistic regression using R package glmnet. The penalty 
parameter λ was optimised using 10- fold cross validation. λ 
corresponding to the minimum mean cross- validated error was 
retained as final penalty parameter in the model.
Predictive performance evaluation
Predictive performance of the final prediction model was 
assessed by computing the area under the receiver operating 
characteristic curve (AUC), using both apparent and internal 
validation with 95% CI. Internal validation using a bootstrap 
method16 17 (performed with R package boot version 1.3-18) 
was employed to correct for overfitting, to generate unbiased 
optimism- adjusted estimates of the C statistic (AUC) with low 
absolute error. Bootstrap estimate of the AUC statistic was 
computed by random sampling with replacement 500 times to 
enable estimation of the optimism corrected AUC.
rEsulTs
Patient demographics and clinical correlations
Two hundered pathobiology of early arthritis cohort patients 
were included: 128/200 (64%) patients were classified as RA1987 
(RA1987+/RA2010+) and 72/200 (36%) as UA. Of the patients 
with UA, 25 were further classified as RA2010 (RA1987−/
RA2010+) (25/200, 12.5%) and 47 remained as UA (RA1987−/
RA2010−) (47/200, 23.5%) (figure 1A). No significant difference 
in mean age, disease duration or erythrocyte sedimentation rate 
(ESR) between groups was demonstrated. However, the RA1987 
group had significantly higher levels of C reactive protein (CRP), 
tender joint count (TJC), swollen joint count (SJC), DAS28, rheu-
matoid factor (RF), anticitrullinated protein antibody (ACPA) and 
Visual Analogue Score (VAS) and significantly higher numbers of 
patients seropositive for RF and ACPA compared with either the 
RA2010 or UA groups (figure 1B). SJC and ACPA titres were the 
only clinical parameters with significant differences between the 
RA2010 and UA groups, indicating that in terms of clinical measures 
of disease activity these two groups are relatively homogenous.
synovial pathotypes distinguish clinical phenotypes 
regardless of disease duration
Synovial biopsies were obtained predominantly from small 
joints (81.5%) (figure 2A). Patients with synovial tissue suitable 
for histological analysis (166/200) were segregated according to 
baseline synovial pathotype (figure 2B) and differences in clin-
ical parameters evaluated. We demonstrated significantly higher 
mean DAS28 within the lympho- myeloid compared with either 
the diffuse- myeloid or pauci- immune group (5.82 vs 4.93 vs 4.86, 
p<0.001). Mean CRP was significantly higher in the lympho- 
myeloid and diffuse- myeloid versus pauci- immune groups 
(16.86 vs 15.52 vs 9.55, p<0.001) and a significantly higher 
number of patients were seropositive for either RF (p=0.012) or 
ACPA (p=0.011) within the lympho- myeloid group (figure 2C). 
To evaluate whether disease duration influenced prevalence of 
synovial pathotype, patients were stratified into four groups 
according to disease duration at baseline (1–3 m, 4–6 m, 7–9 m 
and 10–12 m) and frequency of synovial pathotype determined. 
No significant differences in synovial pathotype frequency at 
each timepoint were demonstrated (p=0.65) (figure 2D).
rA1987 patients display significantly higher levels of synovial 
immune cell infiltration compared to rA2010 and uA patients
Patients were segregated according to pathotype and further into 
RA1987, RA2010 and UA categories. A higher proportion of 
patients within the RA1987 group were categorised as lympho- 
myeloid (vs diffuse myeloid or pauci- immune) (43.5% vs 33% vs 
23.5%) (figure 3A). We also demonstrated a significantly higher 
mean synovitis, CD3 +T cell, CD20 +B cell, CD138 +plasma cell 
and CD68 +SL/L macrophage score between the RA1987 group 
and both the RA2010 and UA groups (p<0.001) (figure 3B). We 
saw no significant differences in synovitis score, mean CD3 +T, 
CD20 +B, CD68 +L or SL macrophage or CD138 +plasma cell 
number between the RA2010 and UA group (figure 3B), indicating 
that these two groups are relatively homogenous in terms of tissue 
pathology.
synovial genes regulating b cell activation and function are 
significantly upregulated in rA1987 patients compared to the 
rA2010/uA groups
Of 200 patients, 145 had RNA available for Nanostring anal-
ysis (95/128 RA1987 patients, 12/25 RA2010 patients and 
38/47 patients with UA) and were analysed for differential gene 
expression (238 genes) between groups.
Comparing RA1987 versus RA2010 groups, we demonstrated a 
significant differential expression of 53 genes (figure 3C). In line 
with the histological analysis, a number of differentially upregu-
lated genes within the RA1987 cohort were involved in mediating 
B cell activation/function (eg, CD79A, CD38, IGJ, CXCL13, IRF4, 
CCL19, CD38, TNFA and IL6). When evaluating gene expression 
between RA1987 and UA groups, we found a similar trend with 
differential upregulation of a number of genes within the RA1987 
cohort mediating B cell activation/function although only CXCL13 
remained significant following correction for multiple comparisons 
(figure 3D). Conversely, when evaluating gene expression between 
the RA2010 and UA cohorts, only seven genes appeared as signif-
icant with a preponderance of differentially upregulated genes 
within the RA2010 cohort mediating cartilage biology (COMP, 
DKK3, INHBA) and none remaining significant after correction 
for multiple comparisons (figure 3E).
Classification as rA1987 criteria at disease onset predicts Pd 
at 12 months
Of 200 patients, 190 had 12- month follow- up data available; 
we examined whether baseline synovial pathotype was associ-
ated with disease evolution. 119/121 (99%) RA1987 patients 
and 19/22 (90%) RA2010 had PD (figure 4A). Within the UA 
cohort, 11/47 (23%) had other diagnoses. Of the remaining 36 
patients, 26/36 (72.2%) had PD, and 10/36 (27.8%) SL. Of the 
patients with UA with PD, 4/26 (15.3%) progressed to fulfil 
2010 ACR/EULAR criteria RA at 12 months. Results demon-
strated a significantly higher proportion of patients with SL 
disease in the UA group compared with the RA2010 or RA1987 
groups and a significantly higher number of patients within 
the RA1987 group with PD (figure 4B). When evaluating the 
effect of baseline pathotype, we demonstrated a higher propor-
tion of patients with a lympho- myeloid versus diffuse- myeloid 
or pauci- imune pathotype (39% vs 32% vs 13%) with PD 
and a higher number of patients with a diffuse- myeloid versus 
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Figure 1 Baseline patient demographics. (A) Baseline classification of patients. Two hundred patients were classified into RA1987 versus UA. 
RA2010 ACR/EULAR criteria were then applied to patients with UA. Final 3 groups obtained showed 47 patients UA (RA1987−/RA2010−), RA2010 
(RA1987−/RA2010+), RA1987 (RA1987+/RA2010+). (B) Demographics according to classification criteria. Data are presented as mean (SD) for 
continue variables and frequency and percentages for categorical variables. Baseline characteristics between the three groups were compared using 
the Kruskal- Wallis or Fisher’s exact test as appropriate. For post hoc comparison, Dunn tests were run and p value from pairwise comparison reported 
in the last three columns of the table. ACPA titre, anticitrullinated protein antibody titre (IU/L); ACPA +ve, anticitrullinated protein antibody (>20 IU/L); 
CRP, C reactive protein; DAS28, Disease Activity Score 28 joints; ESR, erythrocyte sedimentation rate; RF titre, rheumatoid factor titre (IU/mL); RF +ve, 
rheumatoid factor serum positive (>15 IU/L); 28TJC, 28 tender joint count; 28SJC, 28 swollen joint count.
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Figure 2 Patient demographics and disease activity: comparison between pathotypes. (A) Number of biopsy procedures per joint. MCP, 
metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal. (B) Representative images of synovial pathotypes. Sections 
underwent immunohistochemical staining and semiquantitative scoring (0–4) to determine the degree of CD20 +B cells, CD3 +T cells, CD68 +lining) 
and sublining macrophage and CD138 +plasma cell infiltration. Sections were categorised into three pathotypes: (1) pauci- immune (CD68 SL <2 and 
or CD3, CD20, CD138 <1), (2) diffuse myeloid: (CD68SL >2, CD20 <1 and or CD3 >1) and (3) lymphomyeloid: (grade 2–3 CD20 +aggregates, CD20 
>2). Arrow heads indicate positive stain cells. Empty arrows indicate B cell aggregates. (C) Demographic analysis by pathotype. Data are presented as 
mean and SD for numerical variables and frequency and percentage for categorical variables. Baseline characteristics between the three pathotypes 
were compared using a Kruskall- Wallis test and Fisher test (RF and ACPA positivity) as appropriate. Post hoc analysis for significant differences 
using the Dunn test for multiple comparison. A p value of <0.05 was considered statistically significant. (D) Pathotype according to disease duration 
(months) at diagnosis. Absolute values (N) and percentage. A p value of <0.05 was considered statistically significant. ACPA titre, anticitrullinated 
protein antibody titre (IU/L); ACPA +ve, anticitrullinated protein antibody (>20 IU/L); CRP, C reactive protein; DAS28, Disease Activity Score 28 joints; 
ESR, erythrocyte sedimentation rate; RF titre, rheumatoid factor titre (IU/mL); RF +ve, rheumatoid factor serum positive (>15 IU/L); 28TJC, 28 tender 
joint count; 28SJC, 28 swollen joint count.
by copyright.
 o
n
 N
ovem
ber 19, 2019 at University of G
lasgow. Protected
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2019-215751 on 2 O
ctober 2019. Downloaded from
 
1647Lliso- Ribera G, et al. Ann Rheum Dis 2019;78:1642–1652. doi:10.1136/annrheumdis-2019-215751
Early arthritis
Figure 3 Variation in synovial pathobiology according to clinical classification of patients. (A) Baseline clinical classification compared with 
pathotype. Baseline subgroups (RA1987, RA2010 and UA) were compared with pathotype. Fisher test used for analysis. (B) Immune cell infiltration for 
each clinical subgroup. Kruskal- Wallis test for comparison between three groups. Post hoc analysis for significant differences using the Dunn test for 
multiple comparison. (C) (C–E) Gene expression analysis for comparison between subgroups. t- Test for comparison and volcano plot for representative 
image. Positive values represent upregulation and negative values downregulation. Green circles above green horizontal line represents non- corrected 
for multiple analysis expressed genes between groups. Red circles above red line represents corrected p values (Benjamini- Hochberg (BH) method) 
for multiple analysis. (C) Volcano plot RA1987 versus RA2010: difference in gene expression between patient fulfilling RA 1987 ACR criteria and RA 
2010 ACR/EULAR criteria. (D) Volcano plot RA1987 versus UA: difference in gene expression between patient fulfilling RA 1987 ACR criteria and UA. 
(E) Volcano plot RA 2010 versus UA: differences in gene expression between patient fulfilling RA 2010 ACR/EULAR criteria and UA. RA, rheumatoid 
arthritis; UA, undifferentiated arthritis.
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Figure 4 Disease evolution. (A) Patient classification after 12- month follow- up. Disease outcome after 12 months of follow- up for each of the initial 
baseline subgroups (RA1987/RA2010/UA). Disease evolution classified as self- limiting or persistent disease. Other diagnosis as described for those 
who were reclassified after 1 year form UA cohort. (B) Disease evolution by subgroups. Disease evolution was compared with baseline subgroups 
(RA1987, RA2010 and UA). Fisher test used for analysis. (C) Disease evolution by pathotype. Disease evolution was compared with pathotype (pauci- 
immune vs diffuse myeloid vs lymphomyeloid). Fisher test used for analysis. A p value of <0.05 was considered statistically significant. RA, rheumatoid 
arthritis; UA, undifferentiated arthritis.
lympho- myeloid or pauci- immune pathotype (54% vs 18% vs 
27%) with SL (figure 4C).
A baseline lympho-myeloid pathotype significantly associates 
with 12-month requirement for biological therapy
Patients stratified according to diagnostic group or patho-
type were further classified according to 12- month treatment 
requirement: (1) symptomatic treatment, (2) csDMARDs or 
(3) biologics±csDMARDs. A significantly higher proportion 
of RA1987 patients required biologic compared with RA2010 
and UA (27.82% vs 20.83% vs 10.63%) (p<0.001) (figure 5A) 
and importantly, lympho- myeloid (vs diffuse- myeloid or pauci- 
immune) pathotype significantly associated with 12- month 
requirement for biological therapy (57% vs 21% vs 21% 
p=0.02) (figure 5B).
We then compared expression of the 238 genes in the Nanos-
tring panel between patients requiring biological therapy (n=34) 
or not (n=106) and found 119 differentially expressed genes. 
Patients requiring biological therapy had significantly higher 
differential upregulation of genes regulating B and T cell 
proliferation, differentiation and activation (eg, TNFRSF13C, 
CD79A, CD2, CD3E and CD38), genes involved in matrix 
metallopeptidase production/regulation (eg, MMP1 and TIMP1), 
genes involved in cytokine- mediated cellular activation (TNFA, 
TRAF3IP3, IFNA1) and osteoclastogenesis inhibition (DEF6). 
Patients who did not require biological therapy expressed some 
B and T cell regulation genes and B proliferation markers but 
mostly markers of fibroblast proliferation and cartilage turnover 
(figure 5C).
To determine whether disease duration influenced outcome, 
we segregated patients according to 12- month treatment (biolog-
ical therapy or not) and further into disease duration quartiles 
(figure 5D) and demonstrated no significant differences in terms 
of disease duration at diagnosis. Next, we segregated patients 
treated with biological therapy (n=39) according to quartiles 
of disease duration and then synovial pathotype. We found 
no significant differences in patient number in each quartile 
(p=0.3) (figure 5E). These results strongly suggest that synovial 
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Figure 5 (A) Comparison between diagnostic subgroups and treatment outcome at 12- month follow- up. Treatment required was divided in 
three groups: (1) no treatment; (2) csDMARDs only, and (3) csDMARDs ±biologics. Fisher test for analysis. (B) Comparison between pathotype and 
treatment outcome at 12 months. (C) Gene expression analysis, represented in a volcano plot comparison between patient requiring biologics versus 
non- biological group. t- Test comparison for gene difference expression between groups. Positive values represent upregulation and negative values 
downregulation. An adjusted (Benjamini- Hochberg (BH) correction for multiple analysis) p value of <0.01 was considered statistically significant, 
represented as dots above red line. Green dots above green line for gene expression significance when no correction applied for multiple analysis 
(p<0.05). (D) Treatment outcome according to baseline disease duration. Fisher test for analysis. (E) Pathotype according to baseline disease 
duration for biological patient cohort. Fisher test for analysis. A p value of <0.05 was considered statistically significant unless otherwise stated. RA, 
rheumatoid arthritis; UA, undifferentiated arthritis.
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pathotype rather than disease duration influences 12- month 
treatment outcome.
synovial gene expression signatures enhance the 
performance of clinical prediction models for biological 
requirement
To determine whether baseline clinical and gene expression data 
could be combined into a model for predicting requirement for 
biological therapy, we used two complementary approaches: a 
logistic regression model to identify predictive clinical covari-
ates, and a penalised method based on logistic regression with an 
L1 regularisation penalty (LASSO) to identify genes improving 
the clinical model.
Nine baseline clinical covariates were considered as candidates 
in the regression model: disease duration, ESR, CRP, RF, ACPA, 
TJC, SJC, DAS28 and pathotype (two categories, lympho- 
myeloid vs pauci- immune/diffuse- myeloid). Logistic regression 
models using backward forward and bidirectional stepwise selec-
tion resulted in the selection of the same set of clinical covari-
ates: DAS28, pathotype, CRP and TJC. The apparent predictive 
performance of the model evaluated by AUC was 0.78 (95% CI 
0.70 to 0.87).
Genes were selected to improve the clinical model using 
logistic regression with an L1 regularisation penalty (LASSO) 
applied on the four clinical covariates selected by the previous 
logistic regression and the 119 genes identified as being signifi-
cantly differentially expressed between the biological and non- 
biological groups. Models in which clinical predictors were 
penalised or subject to forced inclusion were compared. When 
all predictors were penalised, 11 predictors were retained in the 
final model and when the clinical covariates were not penalised, 
13 predictors were retained (figure 6A). In both the penalised 
and unpenalised clinical model, the apparent prediction perfor-
mance was improved (apparent AUC=0.89, 95% CI 0.83 to 
0.95 and AUC=0.90, 95% CI 0.84 to 0.95) (figure 6B). We 
additionally performed internal validation to correct the AUC 
performance measure for overfitting by calculating the opti-
mism of the AUC for each model by bootstrapped sampling with 
replacement from the original dataset. The optimism corrected 
AUC was 0.75 for the pure clinical model and 0.81 for the clin-
ical and gene model (LASSO) (figure 6C and D) suggesting that 
including both clinical covariates and genes in the model results 
in an improvement of the predictive ability of the model.
dIsCussIOn
These results present a number of novel findings: first, they 
strongly suggest that patients with early inflammatory arthritis 
not fulfilling RA1987 criteria display similar clinical, synovial 
histological and molecular features irrespective of further classi-
fication according to RA2010 or UA criteria. Second, these data 
also suggest that a lympho- myeloid pathotype at disease onset 
predicts poor outcome with patients subsequently requiring 
biological therapy irrespective of clinical classification, and 
finally that the integration of histological and molecular signa-
tures into a clinical prediction model enhances sensitivity/spec-
ificity for predicting whether patients will require biological 
therapy.
To the best of our knowledge, these results emerge from the 
largest synovial tissue treatment- naïve early arthritis cohort 
reported to date and support previous data from early RA cohorts 
suggesting that a synovial immune cell infiltrate characterised by 
a predominant infiltrate of B cells associates with more active 
disease18 and seropositivity for RF and ACPA.10 The results 
suggest that this effect also extends to patients within the UA 
cohort. The clinical similarities between RA2010+/RA1987− 
patients and those with UA have been reported previously8 and 
the data presented herein provide a pathophysiological explana-
tion for this with the demonstration of homogeneous synovial 
cellular and molecular signatures among the two groups. The 
data show a lower percentage of patients requiring biological 
therapy in RA2010+/RA1987− group, in line with the expecta-
tion that the ACR/EULAR 2010 criteria enable an earlier diag-
nosis and thus efficacious treatment. However, it is also possible 
that this group has a milder pathology from the beginning.
Although synovial pathotypes per se do not appear to distin-
guish between patients at risk of developing PD rather than 
SL disease, this is not surprising given the early and treat- to- 
target approach pursued in the study rather than observing 
untreated natural disease evolution. However, when applying 
12- month biological requirement as a prognostic outcome, we 
demonstrated that patients with a lympho- myeloid pathotype 
with a dense synovial infiltrate enriched in B cells and signif-
icant upregulation of T/B cell genes at disease onset predicted 
requirement for subsequent biological therapy and critically 
that this was independent of disease duration. These results 
are consistent with recently published data in early RA which 
reports that the lympho- myeloid pathotype is associated with 
highly agressive disease and worse radiographic outcomes.10 
The current study reinforces these findings demonstrating 
that, at 12- month follow- up, a significantly higher proportion 
of patients classified as lympho- myeloid pathotype required 
biological therapy. The study also calls into question the current 
dogma surrounding ‘an early window of opportunity’ for all 
patients with RA,19–21 suggesting that pathotype rather than 
simply disease duration influences outcome and that intensive 
therapeutic regimens should be targeted to poor prognostic 
pathotypes. This notion is supported by the demonstration that 
the integration of synovial histological and molecular markers 
into a clinical prediction model for biologics use improves sensi-
tivity/specificity from 78.8% to 89%–90% independently from 
disease duration.
Discrepancy with previously reported data suggesting that 
synovial heterogeneity does not relate to clinical phenotypes9 
maybe explained by the fact that in our study the majority of 
biopsies were performed on small joints while in that cohort 
arthroscopic biopsy was restricted to patients with mainly large 
joint involvement and, thus, a potential selection bias.22 Addi-
tionally, the paired histological and molecular data in the largest 
biopsy- driven early arthritis cohort reported to date ensured 
internal validation and high classification accuracy.
Our study does have limitations however, for example, the 
real- life nature of the study did not permit the true evaluation 
of the natural history of the disease or outcome, as no patients 
were left untreated and therapy was not actively withdrawn. 
Also, a treat- to- target approach, treatment escalation and initia-
tion of biological therapy, was determined by treating physicians 
according to NICE guidelines rather than study protocol.
Within these limitations, our results are robust and suggest 
that the introduction of the new RA2010 classification criteria 
brings additional clinical and biological heterogeneity into early 
patient classification compared with the 1987 criteria with 
limited ability of RA2010 criteria alone to predict poor outcome. 
The demonstration that the integration of synovial pathobiolog-
ical markers into clinical algorithms predicting poor outcome 
(requirement for biological therapy) independent of disease 
duration suggests that the ‘window of opportunity’ is wider 
than 6 months and early stratification of biological therapies 
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Figure 6 Prediction model. (A) and (B) Identification of clinical and gene expression features predictive of biological therapy use at 1 year. Logistic 
regression, coupled with backward and stepwise model selection, was applied to baseline clinical parameters against a dependent variable of 
biological therapy use or not at 12 months to select which clinical covariate contributed the most to the prediction. Selected covariates (119 genes+4 
clinical covariates) were entered simultaneously into a logistic model with an L1 regularisation penalty (LASSO) in order to determine the optimal 
sparse prediction model. A similar predictive performance of the model when clinical was seen when results were penalised (blue- dashed line, A) than 
when they were not penalised (red- dotted line, A) with a slightly different set of selected covariates (B). (B) Non- zero weights associated with the final 
variables selected by the LASSO regression. The grey spaces represent the variables that were not selected by the model. (C) and (D) Lambda training 
curve from the final glmnet fitted model. The red dots represent mean binomial deviance using 10- fold cross validation. The error bars represent SE of 
binomial deviance. The vertical dotted lines indicate minimum binomial deviance (λmin) and a more regularised model for which the binomial deviance 
error is within one SE of the minimum binomial deviance (λ1se). λmin was selected, corresponding to 11 non- zero coefficients in the final model for the 
LASSO where clinical were penalised (C) and 13 non- zero coefficients in the final model for the LASSO where clinical were not penalised (D). AUC, 
area under the receiver operating characteristic curve; CRP, C reactive protein; DAS28, Disease Activity Score 28 joints; TJC, tender joint count.
according to poor prognostic synovial pathobiological subtypes 
at disease onset may improve the outcome of these patients.
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